Franco González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Franco González has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Siel
Escuela de Medicina Veterinaria, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago, Chile
2 shared publications - Felipe Díaz-Soler
Escuela de Medicina Veterinaria, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago 8580000, Chile
2 shared publications - Francisco Pérez-Bravo
Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago 7830489, Chile
2 shared publications - Ismael Pereira
Escuela de Medicina Veterinaria, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago 8200010, Chile
2 shared publications Daniela Bustos
Faculty of Life Sciences Universidad Andrés Bello República 239 Santiago Chile
1 shared publicationDaniela Valenci
1 shared publication
Latest Publications
- Open Access
- 10 October 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (10) , 968
Efficacy of a Standardized Low-Dose Insulin Infusion Protocol in the Emergency Stabilization of Diabetic Dogs
Background: Continuous insulin infusion protocols are essential for managing decompensated diabetic dogs, but comparative data between variable and fixed infusion rates are limited. Methods: This prospective observational study evaluated the glycemic response of 21 diabetic dogs treated with a fixed-dose continuous-rate infusion (CRI) of regular insulin at 0.05 IU/kg/h for 12 h. Capillary blood glucose was measured hourly. Statistical analyses included Wilcoxon signed-rank tests, Friedman test, Mann–Whitney U, and Kruskal–Wallis tests. Results: A significant reduction in glucose concentration occurred during the first five hours of infusion (p < 0.0001), followed by a stabilization phase with no further significant changes. No differences in glycemic response were found by sex or breed. The protocol was well tolerated, with no hypoglycemic events observed. Conclusions: A fixed-dose CRI of 0.05 IU/kg/h offers a safe and effective option for acute glycemic control in diabetic dogs, including those with early ketoacidosis. The standardized approach simplifies management without compromising efficacy and supports its inclusion in emergency treatment protocols.
- 10 October 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (10) , 968
Open AccessEfficacy of a Standardized Low-Dose Insulin Infusion Protocol in the Emergency Stabilization of Diabetic Dogs
Background: Continuous insulin infusion protocols are essential for managing decompensated diabetic dogs, but comparative data between variable and fixed infusion rates are limited. Methods: This prospective observational study evaluated the glycemic response of 21 diabetic dogs treated with a fixed-dose continuous-rate infusion (CRI) of regular insulin at 0.05 IU/kg/h for 12 h. Capillary blood glucose was measured hourly. Statistical analyses included Wilcoxon signed-rank tests, Friedman test, Mann–Whitney U, and Kruskal–Wallis tests. Results: A significant reduction in glucose concentration occurred during the first five hours of infusion (p < 0.0001), followed by a stabilization phase with no further significant changes. No differences in glycemic response were found by sex or breed. The protocol was well tolerated, with no hypoglycemic events observed. Conclusions: A fixed-dose CRI of 0.05 IU/kg/h offers a safe and effective option for acute glycemic control in diabetic dogs, including those with early ketoacidosis. The standardized approach simplifies management without compromising efficacy and supports its inclusion in emergency treatment protocols.
- Open Access
- 31 July 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (8) , 721
Chlorambucil Monotherapy in Dogs with Protein-Losing Nephropathy of Probable Immune Origin: A Preliminary Study
Protein-losing nephropathy (PLN) involves a heterogeneous group of pathologies leading to selective glomerular damage and development of renal disease. ICGN, the main cause of PLN, requires immunosuppressive treatment. However, the scientific evidence in veterinary medicine on immunosuppressive therapeutic schemes in this condition is limited. The aim of this study is to describe the clinical and paraclinical evolution of five dogs with PLN, presumably associated with ICGN, treated with chlorambucil as immunosuppressive monotherapy. Suspected IGCN was established by the presence of a urine protein–creatinine ratio (UPC) ≥ 3 without response to standard therapy, hypoalbuminemia < 2, or progressive azotemia. Patients were treated with a dosage range of chlorambucil from 0.16 to 0.4 mg/kg (mean 0.25 mg/kg) every 24 h as the sole immunosuppressant. In the end, 4/5 patients showed significant clinical improvement, 3/3 had resolution of the nephrotic syndrome, 5/5 had a sustained decrease in UPC values during follow-up and no relevant adverse effects were observed. In this report, chlorambucil proved to be a well-tolerated and potentially effective monotherapy for immune-mediated PLN in dogs.
- 31 July 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (8) , 721
Open AccessChlorambucil Monotherapy in Dogs with Protein-Losing Nephropathy of Probable Immune Origin: A Preliminary Study
Protein-losing nephropathy (PLN) involves a heterogeneous group of pathologies leading to selective glomerular damage and development of renal disease. ICGN, the main cause of PLN, requires immunosuppressive treatment. However, the scientific evidence in veterinary medicine on immunosuppressive therapeutic schemes in this condition is limited. The aim of this study is to describe the clinical and paraclinical evolution of five dogs with PLN, presumably associated with ICGN, treated with chlorambucil as immunosuppressive monotherapy. Suspected IGCN was established by the presence of a urine protein–creatinine ratio (UPC) ≥ 3 without response to standard therapy, hypoalbuminemia < 2, or progressive azotemia. Patients were treated with a dosage range of chlorambucil from 0.16 to 0.4 mg/kg (mean 0.25 mg/kg) every 24 h as the sole immunosuppressant. In the end, 4/5 patients showed significant clinical improvement, 3/3 had resolution of the nephrotic syndrome, 5/5 had a sustained decrease in UPC values during follow-up and no relevant adverse effects were observed. In this report, chlorambucil proved to be a well-tolerated and potentially effective monotherapy for immune-mediated PLN in dogs.
- Open Access
- 15 February 2023
- Published by MedCrave Group Kft. in Journal of Dairy, Veterinary & Animal Research
- Vol. 12 (1) , 24-27
Use of ciprofibrate in dogs with hypertriglyceridemia
The objective of this study was to evaluate the effect of ciprofibrate on serum triglyceride concentrations in canine patients. A sample size of 21 canines was study, that had a diagnosis of familial dyslipidemia, and was established with triglyceride levels above 500mg/dl, treatment with ciprofibrate was evaluated at 2 months. The analysis of the variation in triglyceride levels was performed using the non-parametric Wilcoxon matched-pairs signed-rank test. The Wilcoxon test revealed that the triglyceride concentration decreased significantly after two months of treatment with ciprofibrate; from 621 (512 to 1046)mg/dL to 136 (67 to 215)mg/dL (p <0.0001). The difference in medians was -482.0md/dL with a 97.3% confidence interval of -579.0 to -443.0mg/dL. It was concluded that the use of drugs such as ciprofibrate in the treatment of patients with familial hiperlipidemia, had a significant decrease in serum triglyceride concentrations, without generating adverse reactions in this study.
- 15 February 2023
- Published by MedCrave Group Kft. in Journal of Dairy, Veterinary & Animal Research
- Vol. 12 (1) , 24-27
Open AccessUse of ciprofibrate in dogs with hypertriglyceridemia
The objective of this study was to evaluate the effect of ciprofibrate on serum triglyceride concentrations in canine patients. A sample size of 21 canines was study, that had a diagnosis of familial dyslipidemia, and was established with triglyceride levels above 500mg/dl, treatment with ciprofibrate was evaluated at 2 months. The analysis of the variation in triglyceride levels was performed using the non-parametric Wilcoxon matched-pairs signed-rank test. The Wilcoxon test revealed that the triglyceride concentration decreased significantly after two months of treatment with ciprofibrate; from 621 (512 to 1046)mg/dL to 136 (67 to 215)mg/dL (p <0.0001). The difference in medians was -482.0md/dL with a 97.3% confidence interval of -579.0 to -443.0mg/dL. It was concluded that the use of drugs such as ciprofibrate in the treatment of patients with familial hiperlipidemia, had a significant decrease in serum triglyceride concentrations, without generating adverse reactions in this study.
- Open Access
- 8 June 2022
- Published by Veterinary World in Veterinary World
- Vol. 15 (6) , 1408-1412
Analysis of insulin resistance using the non-linear homeostatic model assessment index in overweight canines
Background and Aim: Diabetes mellitus is a carbohydrate metabolism disorder produced mainly by a deficit in insulin production or insulin resistance. The homeostatic model assessment (HOMA) is a broad method for estimating insulin resistance and β-cell function. This study aimed to evaluate the stages of insulin resistance using non-linear HOMA index analysis in normoglycemic normal weight and obese canines. Materials and Methods: Insulin resistance was evaluated using the mathematical HOMA non-linear model in canines with different body and glycemic conditions. Forty canines were studied, including 20 normoglycemic normal weight canines and 20 normoglycemic obese canines. Chi-square statistical test was applied, in which the body condition and HOMA non-linear index were evaluated. The Spearman correlation test was conducted to evaluate the glycemic and insulin variables in both types of canines. Results: The Spearman correlation presented a correlation between increased blood glucose levels and insulin in obese canines, with a correlation of 0.79, while no significant changes in insulin were found in normal weight canines with different blood glucose levels, with a correlation of –0.11. The analysis of the non-linear HOMA index showed significant differences between non-linear HOMA insulin resistance in normal weight and obese canines, with a Chi-square statistic of 16.9424 and p = 0.000039. Canine with increased HOMA 2 showed higher levels of insulin with increasing blood glucose compared to those with normal HOMA 2. Conclusion: The HOMA 2 is a marker for evaluating increased insulin resistance in obese dogs and can be used to determine patients at risk for glycemic alterations.
- 8 June 2022
- Published by Veterinary World in Veterinary World
- Vol. 15 (6) , 1408-1412
Open AccessAnalysis of insulin resistance using the non-linear homeostatic model assessment index in overweight canines
Background and Aim: Diabetes mellitus is a carbohydrate metabolism disorder produced mainly by a deficit in insulin production or insulin resistance. The homeostatic model assessment (HOMA) is a broad method for estimating insulin resistance and β-cell function. This study aimed to evaluate the stages of insulin resistance using non-linear HOMA index analysis in normoglycemic normal weight and obese canines. Materials and Methods: Insulin resistance was evaluated using the mathematical HOMA non-linear model in canines with different body and glycemic conditions. Forty canines were studied, including 20 normoglycemic normal weight canines and 20 normoglycemic obese canines. Chi-square statistical test was applied, in which the body condition and HOMA non-linear index were evaluated. The Spearman correlation test was conducted to evaluate the glycemic and insulin variables in both types of canines. Results: The Spearman correlation presented a correlation between increased blood glucose levels and insulin in obese canines, with a correlation of 0.79, while no significant changes in insulin were found in normal weight canines with different blood glucose levels, with a correlation of –0.11. The analysis of the non-linear HOMA index showed significant differences between non-linear HOMA insulin resistance in normal weight and obese canines, with a Chi-square statistic of 16.9424 and p = 0.000039. Canine with increased HOMA 2 showed higher levels of insulin with increasing blood glucose compared to those with normal HOMA 2. Conclusion: The HOMA 2 is a marker for evaluating increased insulin resistance in obese dogs and can be used to determine patients at risk for glycemic alterations.
- Open Access
- 22 October 2021
- Published by Veterinary World in Veterinary World
- Vol. 14 (10) , 2694-2698
Determination of autoantibodies in dogs with diabetes mellitus
Background and Aim: The classification of diabetes mellitus (DM) in dogs has been controversial as currently canine insulin-dependent DM is classified together with absolute insulin deficiency, non-insulin-dependent DM, and relative insulin deficiency. Studies on human autoantibodies evaluated in canines with DM, such as anti-glutamic acid decarboxylase (GAD65), anti-islet antigen 2 (IA2), and anti-zinc transporter isoform 8 (ZnT8), have been inconclusive. Thus, this study was designed to establish the serological profile of anti-GAD65, anti-IA2, and anti-ZnT8 antibodies in a group of dogs with and without DM. Materials and Methods: Sixty-one dogs, including 31 patients with DM (with and without insulin treatment) and 30 patients without DM (normal weight and obese), were included for determining autoantibodies using a human enzyme-linked immunosorbent assay (ELISA) detection system for type 1 DM. Results: This study found the presence of anti-IA2 antibodies in 58% of the sample (18/31 patients with DM); however, the presence of anti-GAD65 was not detected, and anti-ZnT8 was found in 3 (9.6%) patients with DM. Conclusion: This study showed a higher positive frequency of anti-IA2 antibodies in a sample of canine with DM, indicating that alterations in the signaling vesicle tyrosine phosphatase 2 lead to lower insulin release and thus to an increase in patients' glycemia. These preliminary results should be taken with caution and corroborated by a canine-specific assay when an ELISA is available for such determination.
- 22 October 2021
- Published by Veterinary World in Veterinary World
- Vol. 14 (10) , 2694-2698
Open AccessDetermination of autoantibodies in dogs with diabetes mellitus
Background and Aim: The classification of diabetes mellitus (DM) in dogs has been controversial as currently canine insulin-dependent DM is classified together with absolute insulin deficiency, non-insulin-dependent DM, and relative insulin deficiency. Studies on human autoantibodies evaluated in canines with DM, such as anti-glutamic acid decarboxylase (GAD65), anti-islet antigen 2 (IA2), and anti-zinc transporter isoform 8 (ZnT8), have been inconclusive. Thus, this study was designed to establish the serological profile of anti-GAD65, anti-IA2, and anti-ZnT8 antibodies in a group of dogs with and without DM. Materials and Methods: Sixty-one dogs, including 31 patients with DM (with and without insulin treatment) and 30 patients without DM (normal weight and obese), were included for determining autoantibodies using a human enzyme-linked immunosorbent assay (ELISA) detection system for type 1 DM. Results: This study found the presence of anti-IA2 antibodies in 58% of the sample (18/31 patients with DM); however, the presence of anti-GAD65 was not detected, and anti-ZnT8 was found in 3 (9.6%) patients with DM. Conclusion: This study showed a higher positive frequency of anti-IA2 antibodies in a sample of canine with DM, indicating that alterations in the signaling vesicle tyrosine phosphatase 2 lead to lower insulin release and thus to an increase in patients' glycemia. These preliminary results should be taken with caution and corroborated by a canine-specific assay when an ELISA is available for such determination.